<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04830449</url>
  </required_header>
  <id_info>
    <org_study_id>HM-CHORUS-302</org_study_id>
    <nct_id>NCT04830449</nct_id>
  </id_info>
  <brief_title>Clinical Efficacy and Safety Evaluation of HCP1904-2 in Essential Hypertension Patients</brief_title>
  <official_title>A Multi-center, Randomized, Double-blinded, Active-Controlled, Parallel, Phase III Study to Evaluate the Efficacy and Safety of HCP1904-2 in Essential Hypertension Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanmi Pharmaceutical Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanmi Pharmaceutical Company Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate of efficacy and safety of HCP1904-2 and RLD2001-2&#xD;
      alone in patients with essential hypertension inadequately controlled on RLD2001-2&#xD;
      monotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Multi-center, Randomized, Double-blinded, Active-controlled, Parallel, Phse III Study to&#xD;
      Evaluate the Efficacy and Safety of HCP1904-2 in Essential Hypertension Patients&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 4, 2020</start_date>
  <completion_date type="Anticipated">September 28, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in mean sitting systolic blood pressure(mmHg)</measure>
    <time_frame>Week 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in mean sitting systolic blood pressure(mmHg)</measure>
    <time_frame>Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in mean sitting diastolic blood pressure(mmHg)</measure>
    <time_frame>Week 4,8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in mean pulse blood pressure(mmHg)</measure>
    <time_frame>Week 4,8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responder rate</measure>
    <time_frame>Week 4, 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>target blood pressure reach rate</measure>
    <time_frame>Week 4, 8</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">116</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>HCP1904-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>RLD2001-2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HCP1904-2</intervention_name>
    <description>Take it once daily for 8 weeks orally.</description>
    <arm_group_label>HCP1904-2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RLD2001-2</intervention_name>
    <description>Take it once daily for 8 weeks orally.</description>
    <arm_group_label>RLD2001-2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients over 18 years of age&#xD;
&#xD;
          2. Patients who understands the process of clinical study and voluntarily signs a peer&#xD;
             letter&#xD;
&#xD;
          3. Visit1: A person whose blood pressure measured in visit1 corresponds to the following&#xD;
             conditions&#xD;
&#xD;
               -  Blood pressure medication taken patients: 130mmHg ≤ sitSBP&lt;180mmHg,&#xD;
                  sitDBP&lt;110mmHg&#xD;
&#xD;
               -  Blood pressure medication free patients: 140mmHg ≤ sitSBP&lt;180mmHg, sitDBP&lt;110mmHg&#xD;
&#xD;
          4. Visit2: 140mmHg ≤ sitSBP&lt;180mmHg, sitDBP&lt;110mmHg or if patients are in high risk&#xD;
             group: 130mmHg ≤ sitSBP &lt;180mmHg, sit DBP &lt; 110mmHg&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Difference in mean value of blood pressure measured in both arms of more than 20mmHg&#xD;
             in sitSBP or more than 10mmHg in sitDBP&#xD;
&#xD;
          -  Orthostatic hypotension with symptoms within 3months of visit 1&#xD;
&#xD;
          -  Secondary hypertensive patient or suspected to be&#xD;
&#xD;
          -  Uncontrolled diabetes mellitus(HbA1c &gt; 9%) or type I diabetes mellitus&#xD;
&#xD;
          -  Active gout or hyperuricemia (uric acid ≥ 9mg/dL)&#xD;
&#xD;
          -  Severe heart disease or severe neurovascular disease&#xD;
&#xD;
          -  Severe or malignant retinopathy&#xD;
&#xD;
          -  Clinically significant hematological finding&#xD;
&#xD;
          -  Severe renal diseases (eGFR&lt;30mL/min/1.73m2)&#xD;
&#xD;
          -  Severe hepatopathy or active hepatopathy (AST or ALT normal range ≥ 3 times)&#xD;
&#xD;
          -  Hypokalemia or Hyperkalemia(K&lt;3.5mmol/L or K ≥ 5.5mmol/L)&#xD;
&#xD;
          -  Hyponatremia or Hypernatremia(Na&lt;135mmol/L or Na ≥ 155mmol/L)&#xD;
&#xD;
          -  Hypercalcemia&#xD;
&#xD;
          -  History of malignancy tumor&#xD;
&#xD;
          -  History of autoimmune disease&#xD;
&#xD;
          -  History of alcohol or drug abuse&#xD;
&#xD;
          -  Positive to pregnancy test, nursing mother, intention on pregnancy&#xD;
&#xD;
          -  Considered by investigator as not appropriate to participate in the clinical study&#xD;
             with othe reason&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jin-A Jung, Ph.D.</last_name>
    <phone>82-2-410-9038</phone>
    <email>jajung@hanmi.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seok-Min Kang, Ph.D</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 31, 2021</study_first_submitted>
  <study_first_submitted_qc>March 31, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2021</study_first_posted>
  <last_update_submitted>March 31, 2021</last_update_submitted>
  <last_update_submitted_qc>March 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Losartan</keyword>
  <keyword>Chlorthalidone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Essential Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

